DeepMed Research

The New York State Psychiatric Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1895-01-01

Employees: 251

Market Cap: -

Website: http://www.nyspi.org

Clinical Trials

A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer

Not Applicable

Terminated

Conditions: Pancreatic Cancer
Colon Cancer
Lung Cancer
Prostate Cancer
Depression

Interventions: Behavioral: Psychotherapy

First Posted Date: 2013-09-12

Last Posted Date: 2017-05-19

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 4

Registration Number: NCT01940237

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Mechanisms of Antidepressant Non-Response in Late-Life Depression

Not Applicable

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo oral tablet
Drug: Escitalopram

First Posted Date: 2013-08-29

Last Posted Date: 2020-07-02

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 138

Registration Number: NCT01931202

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression

Not Applicable

Completed

Conditions: Major Depressive Disorder

Interventions: Behavioral: Cognitive Behavioral Therapy

First Posted Date: 2013-08-14

Last Posted Date: 2017-09-19

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 37

Registration Number: NCT01922219

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: olanzapine
Drug: iloperidone

First Posted Date: 2013-08-12

Last Posted Date: 2017-03-20

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 31

Registration Number: NCT01920802

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Citalopram

First Posted Date: 2013-08-08

Last Posted Date: 2020-03-09

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 65

Registration Number: NCT01919216

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers

Phase 2

Withdrawn

Conditions: Cigarette Smoking

Interventions: Drug: D-cycloserine
Drug: Nicotine Replacement Therapy (patch)
Behavioral: Smoking Cue Exposure
Behavioral: Progressive Muscle Relaxation
Drug: Placebo

First Posted Date: 2013-07-25

Last Posted Date: 2020-10-08

Lead Sponsor: New York State Psychiatric Institute

Registration Number: NCT01907594

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

TDCS for Auditory Hallucinations in Schizophrenia

Not Applicable

Completed

Conditions: Schizophrenia

Interventions: Device: transcranial Direct Current Stimulation (tDCS)
Device: Sham tDCS

First Posted Date: 2013-07-12

Last Posted Date: 2020-03-23

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 89

Registration Number: NCT01898299

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States

The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.

Not Applicable

Completed

Conditions: Schizophrenia

Interventions: Other: Standard Psychiatric Treatment
Behavioral: Aerobic Exercise

First Posted Date: 2013-07-11

Last Posted Date: 2014-08-15

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 41

Registration Number: NCT01897064

Locations: 🇺🇸
Columbia University & New York State Psyciatric Institute, New York, New York, United States

Nalrexone Facilitated Discontinuation of Buprenorphine

Phase 1

Completed

Conditions: Stable Opioid Dependence

Interventions: Drug: Naltrexone

First Posted Date: 2013-07-10

Last Posted Date: 2018-06-15

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 6

Registration Number: NCT01895036

Locations: 🇺🇸
NYSPI, New York, New York, United States

Gabapentin Treatment of Benzodiazepine Dependence

Phase 2

Terminated

Conditions: Benzodiazepine Dependence

Interventions: Drug: gabapentin
Drug: Placebo

First Posted Date: 2013-07-09

Last Posted Date: 2019-04-24

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 2

Registration Number: NCT01893632

Locations: 🇺🇸
John Mariani, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy